Showing results (551-560 of 570) with videos related to

Sort By:
Pageof 57
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
JAMA|October 13, 2025
AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial IntelligenceDerek C Angus, Rohan Khera, Tracy Lieu, et al.
Nature Medicine|June 17, 2022
Redefining critical illnessDavid M Maslove, Benjamin Tang, Manu Shankar-Hari, et al.
The Lancet. Respiratory Medicine|April 18, 2025
Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically illElizabeth S Munroe, Alexandra Spicer, Andrea Castellvi-Font, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
The New England Journal of Medicine|February 25, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, Anthony C Gordon, Paul R Mouncey, et al.
JAMA|December 16, 2022
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial, Alisa M Higgins, Lindsay R Berry, et al.
JAMA|March 22, 2022
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial, Charlotte A Bradbury, Patrick R Lawler, et al.
Thorax|May 13, 2025
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Anthony C Gordon, Paul R Mouncey, et al.
The New England Journal of Medicine|October 27, 2023
Simvastatin in Critically Ill Patients with Covid-19, Thomas E Hills, Elizabeth Lorenzi, et al.
Pageof 57